{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.2"},{"groupId":"OG001","value":"20.4"},{"groupId":"OG002","value":"16.5"}]}],"title":"12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.7"},{"groupId":"OG001","value":"15.1"},{"groupId":"OG002","value":"19.8"}]}],"title":"24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.2"},{"groupId":"OG001","value":"29.0"},{"groupId":"OG002","value":"24.2"}]}],"title":"60 Months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"91"}],"units":"Participants"}],"description":"MMR/MR3 was defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL ≤0.1% on the international scale (equivalent to a 3-log reduction in transcript).","groups":[{"description":"Participants received ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG000","title":"Treatment Period: Cohort A: Ponatinib 45 mg"},{"description":"Participants received ponatinib 30 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG001","title":"Treatment Period: Cohort B: Ponatinib 30 mg"},{"description":"Participants received ponatinib 15 mg orally once daily in each 28-day cycle.","id":"OG002","title":"Treatment Period: Cohort C: Ponatinib 15 mg"}],"paramType":"NUMBER","populationDescription":"ITT Population included all participants who were randomized and for whom BCR-ABL1IS could be measured, regardless of whether they received the assigned study drug. Seven participants were randomized but excluded from the ITT population because they had atypical transcripts (transcript type other than b2a2/b3a2) and were not evaluable for BCR-ABL1IS outcome.","reportingStatus":"POSTED","timeFrame":"12, 24 and 60 months after the first dose of study treatment","title":"Percentage of Participants With Major Molecular Response (MMR/MR3)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}